CERT•November 5, 2026 at 12:00 PM UTCPharmaceuticals, Biotechnology & Life Sciences

Certara Reports Double-Digit Software Growth and Updated Outlook; Watch for Sustainability

Read source article

What happened

Certara announced Q3 2026 results highlighting double-digit software revenue growth, an updated full-year outlook, and the appointment of a new Chief Product Officer. The company's Q3 2025 report (per the prior DeepValue master report) showed a return to GAAP profitability and sticky software retention of 102-108%, but the stock traded well above DCF value with high goodwill and thin interest coverage. While the phrase 'solid quarter' and double-digit growth sound encouraging, the press release omits key metrics such as net software retention, bookings, and margin detail, making it difficult to verify whether the growth is organic or acquisition-driven. The master report's criteria for a potential upgrade included sustained double-digit revenue growth with improving margins and retention above 110%, but without concrete numbers we cannot confirm these thresholds have been met. The appointment of a Chief Product Officer suggests a focus on product strategy, which could be positive, but it also may signal a need to reinvigorate the software portfolio amid competitive pressures.

Implication

The update may alleviate some bearish concerns if the growth is high-quality, but it is insufficient to change the fundamental view without seeing the full income statement and cash flow; the balance sheet's $1.24bn in goodwill and intangibles remains a risk, and interest coverage of 1.1x suggests high sensitivity to EBITDA declines; if the company can demonstrate consistent double-digit organic revenue growth and improving cash conversion, the DCF-based fair value could rise, narrowing the gap with the market price; however, the previous analysis suggested the stock was 27% overvalued relative to historical FCF, so even after a positive quarter, the margin of safety is thin; we would need either a price pullback or confirmation of higher, more durable cash flows before upgrading from WAIT.

Thesis delta

The thesis shifts from a pure WAIT to a cautious watch: the company's double-digit software growth and updated outlook partially address the growth concerns, but valuation and balance-sheet risks persist. If subsequent quarters confirm sustained high growth and improving margins, the rating could move to POTENTIAL BUY; if the growth proves acquisition-driven or margins stagnate, WAIT remains appropriate.

Confidence

medium